Beloit Health System First to Use New Wet Macular Degeneration Drug
08/17/2012

Age-related macular degeneration (AMD) is the major cause of blindness in age over 65 because it damages the retina. Beloit Health System ophthalmologists are going to use new Wet Macular Degeneration Drug which will reduce the loss of vision with age.

Online PR News – 17-August-2012 – Beloit, WI – Beloit Health System ophthalmologists are eager to be some of the first in the region to use a new FDA drug now approved to treat wet macular degeneration. Dr. Mario Rojas and Dr. Alice Townshend are scheduling some of their patients for Eylea, the new drug that has been proven to reduce vision loss in wet age-related macular degeneration (AMD).

“We are very anxious to assist these patients who are now suffering from this type of vision disease,” explains Dr. Rojas. “AMD is the leading cause of blindness in the U.S. in adults over the age of 65.”

There are two types of macular degeneration, the “wet” and the “dry” forms. “Dry” AMD is a deterioration of the retinal cells, “wet” is when the blood vessels leak and hemorrhage causing severe vision loss. These new medication help slow or stop the growth of the new blood vessels in wet AMD.

“This is an important, new drug for many seniors who are losing their vision and want to stop or slow the disease as soon as possible,” adds Dr. Townshend. “Even poor vision eyes can stabilize and the studies show some patient start seeing better.”
Previous drugs used for this disease have not been as effective and the time between injections is shorter. Although Eylea has a higher price per injection, Medicare is insuring the cost for seniors who need it.

“The FDA has approved the drug has very safe with no more potential side effects than the previous alternatives. The studies have been very successful,” explains Dr. Rojas. Beloit Clinic ophthalmologists hope to have a supply of the drug later this month.